BG
CNTA

Bollard Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Bollard Group’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,362
Closed -$1.32M – 272
2025
Q2 		$1.32M Buy
+100,362
New +$1.27M 0.03% 111

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bollard Group's CNTA Position: Q3 2025 in Review

Bollard Group sold out of Centessa Pharmaceuticals (CNTA) in Q3 2025, closing a stake of 100,362 shares — an estimated $1.32M sold.

Bollard Group first reported a position in CNTA in Q2 2025 and held it in 1 quarter. The position peaked at $1.32M in Q2 2025. 125 funds tracked by Wall St. Rank hold CNTA as of Q3 2025.

  • Bollard Group reported no remaining Centessa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bollard Group sold 100,362 Centessa Pharmaceuticals shares in Q3 2025, an estimated $1.32M.
  • Bollard Group first reported a position in Centessa Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Bollard Group's Centessa Pharmaceuticals position peaked at $1.32M in Q2 2025.
  • 125 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2025.

Based on Bollard Group's 13F filing for Q3 2025, filed 14 Nov 2025.